We used functional CFI to investigate the effect of the checkpoint-inhibitor anti-PD-1 (nivolumab) or lenalidomide, alone or in combination on the antigen-specific immune responses via LAA-stimulated specific T cells against leukemic cells and also LPC/LSC taken from AML patients. This evidence concerns the gene PDCD1 and acute myeloid leukemia.